Title:
ANTI-HER3 ANTIBODY DRUG CONJUGATE, COMPOSITION THEREOF, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/041006
Kind Code:
A1
Abstract:
Provided is an anti-HER3 antibody drug conjugate, specifically comprising an antibody moiety, an intermediate linker moiety, and a cytotoxic drug moiety which are linked together. The provided antibody drug conjugate achieves excellent anti-tumor activity or/and better safety. The provided antibody drug conjugate can be used for the treatment of cancer.
Inventors:
CHEN TIANXI (CN)
XU TONGJIE (CN)
TANG XIAOQI (CN)
FENG WEIWEI (CN)
ZHANG ZHENGPING (CN)
XU TONGJIE (CN)
TANG XIAOQI (CN)
FENG WEIWEI (CN)
ZHANG ZHENGPING (CN)
Application Number:
PCT/CN2022/119214
Publication Date:
March 23, 2023
Filing Date:
September 16, 2022
Export Citation:
Assignee:
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN)
International Classes:
A61K47/68; A61P35/00; C07D307/20; C07K16/28
Domestic Patent References:
| WO2022022508A1 | 2022-02-03 | |||
| WO2022105878A1 | 2022-05-27 | |||
| WO2022104697A1 | 2022-05-27 | |||
| WO2021148003A1 | 2021-07-29 | |||
| WO2021132166A1 | 2021-07-01 | |||
| WO2021148003A1 | 2021-07-29 | |||
| WO2019200322A1 | 2019-10-17 | |||
| WO2022033578A1 | 2022-02-17 |
Foreign References:
| CN108883198A | 2018-11-23 | |||
| CN110997010A | 2020-04-10 | |||
| CN111116745A | 2020-05-08 | |||
| CN107001463A | 2017-08-01 | |||
| CN109422811A | 2019-03-05 |
Other References:
NAKADA, T. ET AL.: "Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS., vol. 26, no. 6, 8 February 2016 (2016-02-08), XP029436554, DOI: 10.1016/j.bmcl.2016.02.020
no. 2413428-36-9
no. 2413428-36-9
Download PDF: